BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36882326)

  • 1. Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.
    Gertje EC; Janelidze S; van Westen D; Cullen N; Stomrud E; Palmqvist S; Hansson O; Mattsson-Carlgren N
    Neurology; 2023 Apr; 100(17):e1812-e1824. PubMed ID: 36882326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.
    Janelidze S; Mattsson N; Stomrud E; Lindberg O; Palmqvist S; Zetterberg H; Blennow K; Hansson O
    Neurology; 2018 Aug; 91(9):e867-e877. PubMed ID: 30054439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
    Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
    JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
    Cicognola C; Mattsson-Carlgren N; van Westen D; Zetterberg H; Blennow K; Palmqvist S; Ahmadi K; Strandberg O; Stomrud E; Janelidze S; Hansson O
    Neurology; 2023 Jul; 101(1):e30-e39. PubMed ID: 37137722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging.
    Wang Q; Schindler SE; Chen G; Mckay NS; McCullough A; Flores S; Liu J; Sun Z; Wang S; Wang W; Hassenstab J; Cruchaga C; Perrin RJ; Fagan AM; Morris JC; Wang Y; Benzinger TLS
    Neurology; 2024 Feb; 102(4):e208013. PubMed ID: 38315956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.
    Gertje EC; van Westen D; Panizo C; Mattsson-Carlgren N; Hansson O
    Neurology; 2021 Jan; 96(2):e193-e202. PubMed ID: 33046608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
    Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
    Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People.
    Nilsson MH; Tangen GG; Palmqvist S; van Westen D; Mattsson-Carlgren N; Stomrud E; Hansson O
    J Gerontol A Biol Sci Med Sci; 2021 Mar; 76(4):683-691. PubMed ID: 32506119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia.
    Hansson O; Santillo AF; Meeter LH; Nilsson K; Landqvist Waldö M; Nilsson C; Blennow K; van Swieten JC; Janelidze S
    Ann Clin Transl Neurol; 2019 May; 6(5):863-872. PubMed ID: 31139684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition.
    Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N
    Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
    Öhrfelt A; Benedet AL; Ashton NJ; Kvartsberg H; Vandijck M; Weiner MW; Trojanowski JQ; Shaw LM; Zetterberg H; Blennow K;
    Neurology; 2023 Jan; 100(3):e275-e285. PubMed ID: 36192174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of CSF Aβ
    Cullen N; Janelidze S; Palmqvist S; Stomrud E; Mattsson-Carlgren N; Hansson O;
    Neurology; 2022 Mar; 98(9):e958-e967. PubMed ID: 34937781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid.
    Selnes P; Blennow K; Zetterberg H; Grambaite R; Rosengren L; Johnsen L; Stenset V; Fladby T
    Cerebrospinal Fluid Res; 2010 Jul; 7():10. PubMed ID: 20673341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity.
    Tsiknia AA; Sundermann EE; Reas ET; Edland SD; Brewer JB; Galasko D; Banks SJ;
    Alzheimers Res Ther; 2022 Nov; 14(1):160. PubMed ID: 36324151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
    Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
    Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults.
    Guo T; Landau SM; Jagust WJ;
    Alzheimers Res Ther; 2021 Oct; 13(1):174. PubMed ID: 34654465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
    Pillai JA; Bena J; Bekris L; Kodur N; Kasumov T; Leverenz JB; Kashyap SR;
    Alzheimers Res Ther; 2023 Mar; 15(1):54. PubMed ID: 36927447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.